Blinatumomab compared with standard of care for the treatment of adult patients with relapsed/refractory Philadelphia chromosome–positive B‐precursor acute lymphoblastic leukemia

BACKGROUND: A single‐arm, phase 2 trial demonstrated the efficacy and safety of blinatumomab, a bispecific T‐cell–engaging antibody construct, in patients with relapsed/refractory (r/r) Philadelphia chromosome–positive (Ph+) acute lymphoblastic leukemia (ALL), a rare hematologic malignancy with limi...

Celý popis

Uloženo v:
Podrobná bibliografie
Vydáno v:Cancer
Hlavní autoři: Rambaldi, Alessandro, Ribera, Josep‐Maria, Kantarjian, Hagop M., Dombret, Hervé, Ottmann, Oliver G., Stein, Anthony S., Tuglus, Catherine A., Zhao, Xiaoyue, Kim, Christopher, Martinelli, Giovanni
Médium: Artigo
Jazyk:Inglês
Vydáno: John Wiley and Sons Inc. 2019
Témata:
Original Articles
On-line přístup:https://ncbi.nlm.nih.gov/pmc/articles/PMC7003760/
https://ncbi.nlm.nih.gov/pubmed/31626339
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1002/cncr.32558
Tagy: Přidat tag
Žádné tagy, Buďte první, kdo otaguje tento záznam!

Podobné jednotky